hepatitis b + immunoglobulin: clinical use

Prescribing considerations

• Confirm that the indication is prophylaxis rather than treatment of established chronic hepatitis B.
• Assess vaccination history, exposure circumstances, immune response and whether hepatitis B vaccine is also indicated.
• Review IgA deficiency, bleeding risk, hydration and thromboembolic risk factors.
• Record the product name and batch number for traceability.
• Passive antibodies may produce misleading serology and interfere with red-cell antibody testing.

Contraindications and cautions

• Hypersensitivity to the active substance or any excipient.
• Hypersensitivity to human immunoglobulins, particularly in patients with anti-IgA antibodies.

Monitoring

• Observe for hypersensitivity, hypotension and other acute reactions.
• Advise about symptoms of arterial or venous thromboembolism.
• Document the administration site, product and batch details.
• Interpret subsequent serology in the context of passively transferred antibodies.

Clinical pharmacology

A plasma-derived preparation containing predominantly IgG with a high concentration of antibodies to hepatitis B surface antigen. After intramuscular administration, antibodies enter the circulation and provide passive immunity before being catabolised through the reticuloendothelial system.

Formulation and product differences

• The selected product is a colourless to pale-yellow solution for intramuscular injection in single-use vials.
• It contains a small amount of IgA and includes sodium chloride, glycine and sodium acetate.
• It is not an intravenous preparation. Subcutaneous administration is described only when intramuscular injection is contraindicated and no intravenous product is available, with no clinical efficacy data supporting that route.
• It requires refrigerated storage, protection from light and must not be frozen.